TARA
Protara Therapeutics, Inc.Company Information
- Company Name
- Protara Therapeutics, Inc.
- CIK
- CIK0001359931
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TARA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- TARA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-14
- Last sale
- 2026-06-29
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 239,419
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,190,069
- Shares outstanding
- 61,006,766
- Ownership
- 75.71%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 0.77%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 15 | 50 | 13 | 31 | 91 | 163 | 52 | 90 | 52 | 40 | 34 | ||||||
| Marketable Securities Current | 125 | 121 | 106 | 120 | 91 | 33 | 7 | 30 | - | 3 | 26 | 40 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 4 | 4 | 3 | 3 | 2 | 2 | 4 | 3 | 3 | 3 | 4 | ||||||
| Assets Current | 146 | 140 | 160 | 136 | 125 | 127 | 172 | 85 | 92 | 58 | 69 | 78 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Marketable Securities Noncurrent | 19 | 42 | 42 | 1 | 23 | 33 | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Other Assets | 6 | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | - | ||||||
| Assets | 176 | 192 | 209 | 145 | 157 | 169 | 181 | 94 | 102 | 68 | 79 | 88 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 4 | 3 | 5 | 5 | 2 | 4 | 2 | 1 | 1 | 2 | 3 | ||||||
| Accrued Liabilities Current | 7 | 4 | 6 | 4 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 13 | 9 | 11 | 10 | 10 | 7 | 11 | 9 | 6 | 6 | 6 | 7 | ||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | ||||||
| Liabilities | 15 | 11 | 13 | 12 | 13 | 10 | 14 | 12 | 10 | 10 | 11 | 12 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 503 | 502 | 499 | 417 | 416 | 415 | 412 | 314 | 313 | 270 | 269 | 267 | ||||||
| Retained Earnings Accumulated Deficit | -342 | -320 | -302 | -285 | -272 | -257 | -245 | -232 | -221 | -211 | -200 | -190 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | - | -0 | -0 | -0 | ||||||
| Stockholders Equity | 161 | 181 | 196 | 132 | 144 | 158 | 167 | 82 | 92 | 58 | 68 | 77 | ||||||
| Liabilities And Stockholders Equity | 176 | 192 | 209 | 145 | 157 | 169 | 181 | 94 | 102 | 68 | 79 | 88 | ||||||
| Series1 Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Series One Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 59 | 55 | 54 | 39 | 39 | 39 | 35 | 21 | 21 | 11 | 11 | 11 | ||||||
| Shares Outstanding | 59 | 55 | 54 | 39 | 39 | 39 | 35 | 21 | 11 | 11 | 11 | 11 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialProtara Therapeutics, Inc. (TARA) — SEC Financial Statements & Analysis
Protara Therapeutics, Inc. (TARA) is a biological products, (no diagnostic substances) company. Protara Therapeutics, Inc. trades on Nasdaq as: TARA. Protara Therapeutics, Inc. (TARA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Protara Therapeutics, Inc. carries a market cap of $233.05M, a P/E ratio of -3.33x, a P/B ratio of 1.44x, an enterprise value of $215.22M, and an EV/EBITDA multiple of -2.82x. On profitability, it posts a Return on Equity (ROE) of -45.80%, a Return on Assets (ROA) of -42.05%, and a Return on Invested Capital (ROIC) of -60.07%. Per share, it reports EPS of $-1.15, diluted EPS of $-1.15, free cash flow per share of $-1.09, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 37.66% year-over-year and EPS growth of -4.62% year-over-year. On the balance sheet, it maintains a current ratio of 10.97x, a quick ratio of 10.70x, working capital of $132.83M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-66.49M (TTM), and net debt of $-17.82M. Figures sourced from SEC EDGAR.
- Market Cap
- $233.05M
- P/E TTM
- -3.33x
- EPS TTM
- $-1.15
- P/B TTM
- 1.44x
- ROE TTM
- -45.80%
- ROA TTM
- -42.05%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-66.49M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Protara Therapeutics, Inc. in?
Protara Therapeutics, Inc. (TARA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does TARA trade on?
Protara Therapeutics, Inc. (TARA) trades on the Nasdaq.
When was Protara Therapeutics, Inc. (TARA)'s most recent SEC filing?
Protara Therapeutics, Inc. (TARA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is TARA's market cap?
Protara Therapeutics, Inc. (TARA) has a market capitalization of $233.05M as of 2026-06-30.
What is TARA's EPS (earnings per share)?
Protara Therapeutics, Inc. (TARA)'s trailing twelve month EPS is $-1.15 as of 2026-06-30.
What is TARA's ROE (return on equity)?
Protara Therapeutics, Inc. (TARA)'s trailing twelve month Return on Equity (ROE) is -45.80% as of 2026-06-30.
What is TARA's ROA (return on assets)?
Protara Therapeutics, Inc. (TARA)'s trailing twelve month Return on Assets (ROA) is -42.05% as of 2026-06-30.
What is TARA's ROIC (return on invested capital)?
Protara Therapeutics, Inc. (TARA)'s trailing twelve month Return on Invested Capital (ROIC) is -60.07% as of 2026-06-30.
What is TARA's EV/EBITDA?
Protara Therapeutics, Inc. (TARA)'s trailing twelve month EV/EBITDA is -2.82x as of 2026-06-30.